Author: Healio ophthalmology

Single low-dose bevacizumab injection promising for treating type 1 ROP

by  •  • 0 Comments

VANCOUVER, British Columbia — A single low-dose injection of bevacizumab as primary intervention yielded a “good success rate” in treating type 1 retinopathy of prematurity, according to a study presented here.However, “a second bevacizumab injection has not been successful in our experience,” Terry S. Kang, MD, told colleagues at the American Association for Pediatric Ophthalmology and Strabismus meeting.

Read more →

Benefactors endow $25 million gift to USC eye institute

by  •  • 0 Comments

Gayle and Edward Roski have endowed a $25 million gift to the University of Southern California’s Keck School of Medicine eye institute, which is to be named the Gayle and Edward Roski Eye Institute, according to a press release. “This gift will enable us to advance eye research in fields such as ocular imaging, drug delivery, dry eye, stem cell therapies, and public health and policy,” Rohit Varma, MD, MPH, professor and chair of the department of ophthalmology and interim dean of the Keck School of Medicine, said in the (Read more...)

Endothelial keratoplasty continues to evolve toward greater achievements

by  •  • 0 Comments

Endothelial keratoplasty has been one of the most remarkable advances in ophthalmology, rapidly evolving through progressive refinement and widely adopted all over the world. Today in the U.S., Europe and most parts of Asia, 90% of situations in which corneal transplantation is needed and the main problem is the endothelium are dealt with by endothelial keratoplasty techniques rather than full-thickness transplantation. It is particularly in the last 2 or 3 years that initial resistance to this surgery — which was considered a difficult procedure and not within everyone’s reach — (Read more...)

Latest developments in endothelial keratoplasty aimed at graftless surgery, regeneration

by  •  • 0 Comments

Endothelial keratoplasty has created a revolutionary paradigm shift in the treatment of corneal endothelial disease. Through several iterations the procedure has become increasingly selective, and further developments are now on the horizon. If the developments live up to expectations, a donor graft might no longer be needed, at least in some of the cases.“We now have PK, DSEK or DMEK, but in addition to that, we may be able to treat endothelial dysfunction by injected cells or by simple instillation of eye drops,” Shigeru Kinoshita, MD, PhD, said.

Read more (Read more...)

Rosacea increases risk for Parkinson’s disease

by  •  • 0 Comments

Researchers identified an increased risk for Parkinson’s disease in patients with rosacea, according to data published in JAMA Neurology.This risk further increased in patients specifically with ocular rosacea, according to Alexander Egeberg, MD, PhD, department of dermato-allergology, Herlev and Gentofte Hospital, University of Copenhagen, and colleagues.

Read more →

Pfizer, Allergan terminate proposed merger

by  •  • 0 Comments

Pfizer and Allergan plc announced today that the merger agreement between the two companies has been terminated by mutual agreement.Pfizer said in a press release that the decision was based on actions announced by the U.S. Department of Treasury on April 4, “which the companies concluded qualified as an ‘Adverse Tax Law Change’ under the merger agreement.”

Read more →

Pfizer, Allergan terminate proposed merger

by  •  • 0 Comments

Pfizer and Allergan plc announced today that the merger agreement between the two companies has been terminated by mutual agreement.Pfizer said in a press release that the decision was based on actions announced by the U.S. Department of Treasury on April 4, “which the companies concluded qualified as an ‘Adverse Tax Law Change’ under the merger agreement.”

Read more →

EyeGate reports $8.4 million net loss in 2015

by  •  • 0 Comments

EyeGate Pharmaceuticals reported an $8.4 million net loss in 2015 compared with $1.6 million in 2014, according to a company press release. Research and development expenses were reported at $2.7 million in 2015 compared with $0.5 million in 2014. The increase was attributed to clinical activity for EGP-437, the company’s leading drug candidate in clinical trials for treatment of anterior uveitis and macular edema.

Read more →

Acucela, University of Manchester enter licensing agreement for gene therapy

by  •  • 0 Comments

Acucela has entered into an exclusive licensing agreement with the University of Manchester to develop and commercialize the university’s human rhodopsin-based optogenetic gene therapy to treat retinitis pigmentosa and related conditions, according to a company press release. “We are extremely excited to enter into this collaboration with the University of Manchester and to begin the important development work needed to unlock the potential of optogenetic gene therapy to improve visual function in patients who have lost much of their vision as well as their hope,” Ryo Kubota, MD, PhD, chairman, (Read more...)

Publication Exclusive: Troubleshooting the initiation of cyclosporine for dry eye

by  •  • 0 Comments

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.Dry eye disease is one of the most frequently seen problems in the eye care professional’s office. Cyclosporine drops have become the mainstay of treatment of this condition. Some physicians have noted difficulty with the initiation of cyclosporine due to the delay in onset and the subjective irritation some patients note upon instillation. This month, Jonathan D. Solomon, MD, and Cynthia (Read more...)